|
Acute leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
This study demonstrated that the AKT1 E17K mutation occurs in breast cancers at a low frequency, and that it is rare in other common cancers, including colorectal, lung, gastric and hepatocellular carcinomas and acute leukaemias.
|
18392055 |
2008 |
|
Adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We detected a missense mutations G-->A transition at nucleotide 49 (that results in the E17K substitution) in two squamous cell carcinoma (2/36) but not in adenocarcinoma (0/53).
|
18256540 |
2008 |
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The AKT1 G49A (E17K) mutation was found in 2/44 (4.8%) bladder cancer cell lines and 5/184 (2.7%) bladder tumours.
|
19802009 |
2010 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
The data suggest that AKT1 (E17K) is the most likely disease driver in certain breast cancer patients.
|
27515171 |
2016 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Both AKT inhibitors caused highly significant growth inhibition of breast cancer explant models with AKT1(E17K) mutation.
|
26351323 |
2015 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
AKT1 mutations (E17K) have been found in 1.4-8% of breast cancer patients.
|
29086897 |
2018 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Analysis of TCGA breast cancer data revealed that the mRNA expression, total protein levels, and phosphorylation of various RTKs are decreased in human tumors harboring AKT1(E17K).
|
27004402 |
2016 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
The results obtained in this study suggest that Akti-1/2 might be a better inhibitor for the treatment of BC caused by the E17K mutation in AKT1.
|
31698236 |
2019 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
AKT1 E17K is a bona fide oncogene in a human luminal breast cancer context.
|
23888070 |
2013 |
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
To show the involvement of AKT1(E17K) directly in v-Abl-mediated tumorigenesis, we infected bone marrow cells from mice with bicistronic retroviruses encoding v-Abl and either wild-type or the mutant AKT1.
|
20440266 |
2010 |
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Moreover, SUMOylation loss dramatically reduced Akt1 E17K-mediated cell proliferation, cell migration, and tumorigenesis.
|
23884910 |
2013 |
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Overall, the evidence indicates that the molecular mechanism underlying E17K oncogenesis is a broadened target lipid selectivity that allows high-affinity binding to PI(4,5)P(2).
|
18954143 |
2008 |
|
Carcinogenesis
|
|
0.040 |
GeneticVariation
|
BEFREE |
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
|
27004402 |
2016 |
|
Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Likewise, 3 of 78 (3.8%) invasive carcinomas showed an AKT1 E17K mutation, and this mutation was identified in matching in situ carcinoma in both informative cases.
|
19418217 |
2010 |
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
The AKT1 G49A (E17K) mutation was found in 2/44 (4.8%) bladder cancer cell lines and 5/184 (2.7%) bladder tumours.
|
19802009 |
2010 |
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data provide evidence that, although AKT1 mutations are apparently rare in lung cancer (1.9%), the oncogenic properties of E17K-AKT1 may contribute to the development of a fraction of lung carcinoma with squamous histotype (5.5%).
|
18256540 |
2008 |
|
Carcinoma, Transitional Cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
Using chip-based matrix-assisted laser desorption-time-of-flight (MALDI-TOF) mass spectrometer, AKT1 E17K mutation was searched in 26 total RNA samples obtained from 26 patients known to have urothelial carcinoma.
|
19389506 |
2009 |
|
Childhood Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice.
|
20440266 |
2010 |
|
Childhood Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice.
|
17921701 |
2007 |
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
|
25714871 |
2015 |
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a rare activating mutation of AKT1 (E17K) has been reported in breast, ovarian, and colorectal cancers.
|
18813315 |
2008 |
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Both maintained T-cell responses in peripheral blood to oncogenic driver mutations - BRAF-N581I in the NSCLC and AKT1-E17K in the CRC - years after treatment initiation.
|
30744692 |
2019 |
|
Endometrial adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Compound 21a also served as a potent inhibitor of the AKT1-E17K mutant protein and inhibited tumor growth in a human xenograft mouse model of endometrial adenocarcinoma.
|
27305487 |
2016 |
|
Endometrial Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We identified the AKT1 E17K mutation in 4% of endometrial carcinomas.
|
19853286 |
2010 |
|
Endometrial Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We analysed the presence of the AKT1 (E17K) mutation in 89 endometrial cancer tissue specimens and in 12 endometrial cancer cell lines by PCR and direct sequencing.
|
19491896 |
2009 |